A Predictive Model for Clinical Asthma Exacerbations Using Albuterol eMDPI (ProAir Digihaler): A Twelve-Week, Open-Label Study

Guilherme Safioti, MD; Lena Granovsky, PhD; Thomas Li, PhD; Michael Reich, PhD; Shahar Cohen, PhD; Yonatan Hadar, MSc; Roy Pleasants, PharmD; Henry Chrystyn, MPharm, PhD; Tanisha Hill, PhD; Michael DePietro, MD

1Teva Pharmaceutical Industries, Amsterdam, Netherlands
2Teva Pharmaceuticals, Petah Tikva, Israel
3Teva Branded Pharmaceuticals R&D Inc, Malvern, PA, United States
4Yellow Road, Petah Tikva, Israel
5Division of Pulmonary Medicine and Critical Care, School of Medicine, University of North Carolina, Chapel Hill, NC, United States
6Inhalation Consultancy Ltd, Leeds, United Kingdom

Corresponding Author:
Guilherme Safioti, MD
Teva Pharmaceutical Industries
107 Piet Heinkade
Amsterdam, 1019 BR
Netherlands
Phone: +31 020 2193000
Email: Guilherme.Safioti@tevapharm.com

Abstract

Background: The ability to identify an impending clinical asthma exacerbation (CAE) would improve asthma action plans and provide opportunities for pre-emptive treatment. Increased use of inhaled rescue medications, such as albuterol, has been observed in the days prior to a CAE, but other potential predictive factors are poorly understood. Approved by the US Food and Drug Administration (FDA) in late 2018, ProAir Digihaler with built-in sensors registers when patients use the inhaler and has been shown previously to accurately measure both peak inspiratory flow and inhalation volume, confirming the device’s ability to reliably record objective information on inhaler usage and technique.

Objective: Data collected from the ProAir Digihaler provides, for the first time, a more complete picture of patients’ use of inhaled medication, and thereby offers an opportunity to develop a predictive model of an impending CAE, and the potential to better implement asthma action plans and facilitate early treatment.

Methods: Patients (≥18 years old) with exacerbation-prone asthma were recruited to a 12-week, open-label study. Patients used the ProAir Digihaler (albuterol 90 µg 1–2 inhalations q4 hours) as needed. The electronic component of Digihaler recorded each use and inhalation variables (peak inspiratory flow, volume inhaled, time to peak flow, and inhalation duration). Data were downloaded from the inhalers and, together with clinical data, subjected to a machine-learning algorithm to develop models predictive of an impending CAE as defined by the need for oral corticosteroids. The generated model was evaluated by receiver operating characteristic (ROC) curve analysis.

Results: Three hundred and sixty patients made ≥1 valid inhalation from the Digihaler and were included in the analysis. Of these, 64 patients experienced a total of 78 CAEs. The strongest predictive factor during the 5 days before a CAE was the average number of albuterol inhalations per day. The predictive model was strengthened by supplementing these data with other inhalation features collected by Digihaler, including peak inhalation flow, inhalation volume, night-time usage, and trends of these parameters over time. This model predicted an impending exacerbation over the 5 days with a ROC AUC value of 0.75.

Conclusions: This study represents, to our knowledge, the first successful attempt to develop a model to predict CAE derived from the use of a rescue medication inhaler device equipped with an integrated sensor and capable of measuring inhalation parameters. The predictive power of the model would benefit from further development with larger populations of asthma patients.

(iproc 2019;5(1):e15173) doi: 10.2196/15173

http://www.iproc.org/2019/1/e15173/
KEYWORDS
asthma; digital; inhaler; predictive; digital inhaler; predictive model; clinical asthma exacerbation; albuterol